Latest Breaking News On - Thomas pike - Page 4 : comparemela.com

Fortrea (NASDAQ:FTRE) Shares Gap Up to $28 72

Fortrea (NASDAQ:FTRE) Shares Gap Up to $28 72
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesThomas pikePeterm neupertSecurities exchange commissionFortrea holdings incFortrea holdingsGet free reportExchange commissionDirector peterHoldings incFortrea daily

Fortrea (NASDAQ:FTRE) Now Covered by Analysts at Evercore ISI

Evercore ISI started coverage on shares of Fortrea (NASDAQ:FTRE – Free Report) in a report released on Thursday, Marketbeat Ratings reports. The brokerage issued an inline rating and a $31.00 price target on the stock. Several other brokerages also recently issued reports on FTRE. Bank of America started coverage on shares of Fortrea in a […]

United statesPeterm neupertThomas pikeFortrea holdings incSecurities exchange commissionFree reportMarketbeat ratingsGet free reportExchange commissionDirector peterHoldings incFortrea dailyNasdaq ftreInitiated coverageEvercore isi

Fortrea (NASDAQ:FTRE) Shares Gap Up After Insider Buying Activity

Fortrea (NASDAQ:FTRE) Shares Gap Up After Insider Buying Activity
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesPeterm neupertThomas pikeFortrea holdings incSecurities exchange commissionFortrea holdingsGet free reportDirector peterExchange commissionHoldings incFortrea daily

Labcorp Appoints Thomas Pike To Lead Clinical Development Business

WASHINGTON (dpa-AFX) - Labcorp (LH) announced that Thomas Pike will join the company as president and chief executive officer of its Drug Development Clinical Development business unit on Jan.

United statesThomas pikeTom pikeDrug development clinicalLaboratory corp of america aktieClinical development

Labcorp names CEO for spin-off Clinical Business unit

Labcorp said Thursday that health-care industry veteran Thomas Pike has been hired as chief executive of its planned Clinical Business spin-off.

United statesAdam schechterThomas pikePaul kirchgraberExchange commissionLabcorp drug developmentQuintiles transnational holdings incLaboratory corpAmerica holdingsClinical developmentClinical businessQuintiles transnational holdingsDrug developmentBowman grayDom pikePin off